CRAFA
PEPTIDE & COMPOUND ANALYSIS

# CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-0138
Issued: 2026-09-02

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

## PRODUCT IDENTIFICATION

| | | |
|---|---|---|
| PRODUCT<br>BPC-157 | SKU / INTERNAL CODE<br>CRF-2026-0138 | PRESENTATION<br>Lyophilised powder, 10 mg vial |
| BATCH NUMBER<br>CRF-2026-0138 | SAMPLE RECEIVED<br>2026-08-26 | PRODUCTION DATE<br>2026-08-22 |
| ANALYSIS DATE<br>2026-08-31 | EXPIRY / RETEST DATE<br>2028-08-31 | MOLECULAR FORMULA (REFERENCE)<br>C62H98N16O22 |
| MOLECULAR WEIGHT (G/MOL; REFERENCE)<br>1419.53 | CAS (REFERENCE)<br>137525-51-0 | |

*Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.*

## ANALYTICAL METHOD — HPLC

| | | |
|---|---|---|
| INSTRUMENT<br>Bruker ultrafleXtreme | COLUMN<br>C18 4.6×150mm | COLUMN TEMPERATURE<br>35°C |
| MOBILE PHASE A<br>0.1% TFA H2O | MOBILE PHASE B<br>ACN | FLOW RATE<br>1.0 mL/min |
| DETECTION WAVELENGTH<br>214 nm | INJECTION VOLUME<br>10 µL | SAMPLE CONCENTRATION<br>1.0 mg/mL |
| DILUENT<br>— | RETENTION TIME (MAIN PEAK)<br>9.1 min | |

Recorded methods: HPLC-UV (214 nm) · MALDI-TOF

## RESULTS

| Test | Acceptance Criteria | Result | Verdict |
|---|---|---|---|
| HPLC Purity (% area) | ≥98.0% | 99.8% | PASS |
| Identity (MALDI-TOF) | 1419.5 ±2% | Obs: 1419.5 [M+H]+ | PASS |
| Quantity found | 95.0–105.0% | 9.71 mg (97.1%) | PASS |
| Endotoxin | <1.0 EU/mg | <0.4 EU/mg | PASS |
| Heavy metals | <10 ppm | <5 ppm | PASS |

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Acceptable for research use. Single 1.2% impurity at RT 8.4 min — likely truncated sequence, no toxicology concern.

crafa

CRAFA